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Abstract
Background: The natural history of cutaneous HPV is unclear and in particular, seroprevalence among individuals with different
levels of immune function and ethnicity is unknown. As part of a study of cutaneous squamous cell carcinoma (SCC) and HPV
among organ transplant recipients (OTR) from London, we investigated the seroprevalence and risk factors for 34 HPV types
(detected using Luminex technology) among 409 OTR patients without skin cancer (243 Caucasians and 166 non-Caucasians),
367 individuals with end stage renal failure on dialysis (222 Caucasians and 145 non-Caucasians) and 152 immunocompetent (IC)
individuals without skin cancer (102 Caucasians and 50 non-Caucasians) to compare the HPV seroprevalence in patients with
differing immune status and ethnicity. In total, seroprevalence data from 928 individuals, all from London, was available.
Results: Overall, no difference between HPV seroprevalence by immune status was observed (P = 0.3) among Caucasian or
among non-Caucasian individuals, with seroprevalence varying from 87% to 94% across different immune status and ethnic
groups. Those individuals seropositive to multiple types of one genus were more likely to be seroreactive to multiple types of
another genus, independent of immune status or ethnicity. Lower seroprevalence for gammaHPV 4, and to a lesser extent
gammaHPV 48, were observed among OTR compared to IC and dialysis patients. Higher seroprevalence against antibodies to
betaHPV 93 were detected more frequently in non-Caucasians than Caucasians whereas muHPV 1 and, to a lesser extent,
gammaHPV 4 were found more frequently among Caucasians - these findings were independent of immune status. Within non-
Caucasian subgroups, the seroprevalence of 8 HPV (alpha-mucosal HPV16 and 13, alpha-cutaneous HPV7 and 2, betaHPV8, 17,
23 and 38) was significantly (P < 0.02) higher in Black compared to Asian patients. HPV16 being sexually transmitted, this might
suggest a potential sexual route of transmission for some beta HPV types.
Conclusion: We did not observe major disturbance in antibody response between immunocompetent, dialysis and OTR
individuals, but significant differences in HPV seroprevalence were identified according to ethnicity. Further research is needed
to clarify the natural history of cutaneous HPV, particularly given the growing research interest in its possible role in the
pathogenesis of cutaneous SCC.
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Background
Genital human papillomaviruses (HPV6 and HPV11) are
the most common sexually transmitted infectious agents
in the UK [1]. Associations include younger age, lifetime
number of sexual partners, socio economic status and eth-
nicity (black>white>asian) [2]. A higher seroprevalence of
mucosal type HPV16, an important cause of cervical can-
cer, has also been associated with these factors and, addi-
tionally to female sex, to men who have sex with men and
to urban location [3]. The natural history and risk factors
associated with mucosal HPV infection have been studied
intensively [4] but the natural history of cutaneous HPV is
less clear [5].
Here, we investigate the seroprevalence for 34 HPV types
detected using Luminex technology among people in Lon-
don with different immune status and ethnicity. Informa-
tion on 409 OTR without skin cancer (243 Caucasian and
166 non-Caucasian) and 152 immunocompetent (IC)
individuals (102 Caucasians and 50 non-Caucasians)
were included. Patients with end-stage renal disease on
dialysis (222 Caucasians and 145 non-Caucasians), at
increased risk of infections and cancers [6] probably due
to abnormalities of the immune functions [7,8], were also
included.
Methods
Study population
The present study was conducted as part of research exam-
ining the relationship between antibodies against HPV-L1
antigens for 34 HPV types and cutaneous squamous cell
carcinoma among OTR. Further details of the study meth-
ods can be found elsewhere [9]. Briefly, a nested case-con-
trol study was conducted in a cohort of transplant
recipients from Barts and London NHS Trust, recruited
between October 2002 and August 2006. In London, all
patients have access to a dedicated dermatology clinic fol-
lowing their usual visit to the transplant centre and
undergo routine skin examinations, at which all benign
and malignant lesions are recorder and treated if neces-
sary. A trained nurse interviewed participants using a
standard questionnaire and obtained demographic
details, smoking and alcohol history, medical history,
self-reported ultraviolet (UV) radiation exposure, history
of viral infection, transplantation details, gynaecological
and reproductive history and questions on crowding
throughout life. A blood sample was taken and serum,
buffy coat and red blood cells were separated, aliquoted
and frozen at -80°Celsius.
In order to assess whether the seroprevalence of HPV was
affected by immune status, IC patients were also recruited,
and included Caucasians and non-Caucasians without a
history of skin cancer enrolled from ophthalmology, plas-
tic surgery or phlebotomy departments. A short question-
naire on basic socio-demographic details (sex, date of
birth and ethnicity) and skin cancer history was com-
pleted and a blood sample was obtained. In order to eval-
uate the influence of renal failure pre-transplantation on
HPV seroprevalence, stored sera from Caucasian and non-
Caucasian dialysis patients with no history of transplanta-
tion, were also included. Skin cancer history was not avail-
able for these patients, although it was known that none
had previously attended the dermatology department for
treatment of skin cancer. Basic socio-demographic details
(sex, date of birth and ethnicity) were provided from the
hospital renal database.
In total, information on 409 OTR without skin cancer
(243 Caucasian and 166 non-Caucasian of whom 5
patients [1%] with a solid organ graft other than kidney),
152 immunocompetent (IC) individuals (102 Caucasians
and 50 non-Caucasians) and 367 patients with end-stage
renal disease on dialysis (222 Caucasians and 145 non-
Caucasians) were included.
Ethical approval
The study has been approved by the East London and City
Health Authority Research Ethics Committee.
HPV multiplex serology
HPV antibody detection was performed by multiplex
serology, an antibody detection method that is based on a
glutathione  S-transferase (GST) capture enzyme-linked
immunosorbent assay, as previously described [10,11] in
combination with fluorescent bead technology [12,13].
All antigens were expressed in E. coli as double fusion of
full-length viral proteins with a N-terminal GST domain
and a C-terminal peptide consisting of the last 11 amino
acids from the large T antigen of simian virus 40 [10]. The
expression constructs for the full length L1 proteins of all
HPV types analyzed here (mucosal alpha: 6, 13 and 16;
cutaneous alpha: 2, 3, 7 and 27; beta: 5, 8, 9, 15, 17, 20,
23, 24, 36, 38, 49, 75, 76, 92, 93, 96; gamma: 4, 65, 95,
48, 50, 60; nu: 41; mu: 1, other types: 101 and 103) are
described in detail elsewhere [5,11,14]. Glutathione-
casein was coupled to internally fluorescence-labeled pol-
ystyrene beads (Luminex, Austin, TX), and fusion proteins
were affinity-purified on the beads directly in a one-step
procedure. Beads with GST and the C-terminal peptide
alone were prepared for background determination. Bind-
ing of the antigens (i.e. the GST fusion proteins) to vari-
ous bead sets was verified with a monoclonal antibody
against the common C-terminal peptide [10]. The differ-
ently labelled bead sets carrying different antigens were
mixed and incubated in 96-well plates with human
plasma diluted 1:100 in blocking buffer, as described pre-
viously [13]. The analyses were performed blinded with
respect to the immune status of the samples. Antibodies
bound to the beads via the viral antigens were thenInfectious Agents and Cancer 2009, 4:14 http://www.infectagentscancer.com/content/4/1/14
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stained with biotinylated anti-human immunoglobulin
and fluorescent reporter conjugate streptavidin-R-phyco-
erythrin. Antibodies bound to antigens on beads were
quantified via the reporter fluorescence in the Luminex
analyzer, which also identified the internal bead colour
and thus the antigen carried by the bead. Antibody quan-
tity was determined as the median R-phycoerythrin fluo-
rescence intensity (MFI) from at least 100 beads of the
same internal colour after subtraction of background reac-
tivity (GST and C-terminal peptide alone). The assay
reproducibility was high (R2 = 0.97) [12,15]. More infor-
mation on quality control has been described elswewhere
[15]. For all HPV types but HPV6 analyzed here, MFI cut-
offs to define seropositivity for all antigens were set to 200
MFI as described and discussed previously [5,14]. To
reduce the influence of borderline seropositive sera, a
stringent (doubled) cut-off of 400 MFI was applied to
HPV6. In our previous analysis [14], data analysis using
geometric mean MFI values instead of cut-off values did
not materially change the results.
Statistical methods
To assess the relationship between seropositivity to a sin-
gle HPV type and ethnicity or immune status, logistic
regression adjusted for sex, age at recruitment (<45, 45-
59, ≥60 years) and, if appropriate, time since transplanta-
tion (<5, 5 to 9, ≥10 years) was applied. Where results are
presented in the form of plots, black squares indicate the
point estimates and horizontal lines represent 95% confi-
dence intervals (CI). The area of the square is proportional
to the amount of statistical information available (inverse
of the variance of the logarithm of the estimate). To exam-
ine the association between multiple HPV seropositivity
and ethnicity or immune status, negative binomial regres-
sion adjusted for the same factors was used since over-dis-
persion was observed when Poisson models were fitted
(likelihood ratio test for the null hypothesis of no overd-
ispersion was rejected with P < 0.001). Linear regression
was used to compare the means between several groups.
Skin type of non-Caucasians was defined using Fitzpatrick
classification scale as follows (V) Asian, Middle Eastern
and (VI) African/Afro-Caribbean. Detailed ethnicity infor-
mation was only available for OTR and was defined as
Caucasian (those who identified themselves as 'White'
and were usually individuals of European descent) and
non-Caucasian (those who identified themselves as
'Asian', 'Far Eastern', 'Black' or other' - usually individuals
of non-European descent). Associations between age at
recruitment, sex and HPV seropositivity was examined by
immune status using logistic regression among Caucasian
patients.
Sensitivity analysis was performed to compare HPV sero-
prevalence among IC, dialysis and transplant patients
with kidney graft only. To deal with multiple significant
tests the level of statistical significance was set to 1% and
when a sufficient number of patients was available, agree-
ment of results across population was used to detect gen-
uine associations. Missing value categories were added to
adjustment variables with incomplete information in
order to retain all the observations in the analyses. Likeli-
hood ratio tests were used to assess heterogeneity tests. All
P-values are two-sided. Statistical analyses were carried
out using STATA 9 (StataCorp, 2005).
Results
Participants
Table 1 shows the distribution of sex, time since trans-
plantation and age at recruitment by ethnicity and
immune status. In total, 243 Caucasian and 166 non-Cau-
Table 1: Descriptive statistics for age at recruitment, sex and time since transplantation by immune status and ethnicity
CAUCASIANS NON-CAUCASIANS
Immune status Number OTR IC dialysis OTR IC dialysis
N = 243 N = 102 N = 222 N = 166 N = 50 N = 145
sex
Ratio (M/F) 1.6 (150/93) 1.0 (50/52) 1.5 (132/90) 1.4 (96/70) 0.6 (18/32) 1.3 (83/62)
age at recruitment (yr) P-Het. = 0.1 P-Het. = 0.01
Mean [SD]
range
47 [13] 
21 to 83
53 [18]
23 to 91
54 [14]
19 to 85
47 [12]
20 to 78
41 [16]
17 to 73
48 [13]
18 to 80
time since transplantation (yr) P-value1 < 0.001 P-value1 = 0.01
Mean [SD]
range
9.6 [7.1]
1 mth to 29.0 yr
NA NA 7.0 [6.4]
3 mths to 28.4 yr
NA NA
P-valueCaucasian versus non Caucasian 
OTR
1 = 0.0002
N: Total number; no: number; IC: immunocompetent; OTR: organ transplant patients; mth: month; yr: year; NA: not available;
M: male; F: female; Het.: P-value for heterogeneity using logistic regression model; 1: P-value for difference between means using linear regression 
model.Infectious Agents and Cancer 2009, 4:14 http://www.infectagentscancer.com/content/4/1/14
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casian OTR (5 patients [1%] with a solid organ graft other
than kidney) without skin cancer, 102 Caucasian and 50
non-Caucasian IC patients without skin cancer, and 222
Caucasian and 145 non-Caucasian dialysis patients were
available for analysis. Overall, seroprevalence data from
928 individuals were therefore available. Among Cauca-
sian patients, OTR were on average younger than IC (P =
0.003) and dialysis patients (P < 0.001) but there was no
statistical difference between the distribution of males
and females in the 3 groups. Among non-Caucasian
patients, the proportion of women was higher among
immunocompetent individuals than OTR or dialysis
patients and, IC individuals were also on average younger
than the 2 other groups (P-heterogeneity = 0.01). Cauca-
sian patients tended to have been transplanted for longer
than non-Caucasians (mean [SD] in years: 9.6 [7.1] versus
7.0 [6.4]; P = 0.0002).
Of the 166 non-Caucasian transplant recipients, 54%
identified themselves as Asian, 31% as Black, 8% as Far
Eastern and 7% as other ethnic group. In terms of country
of birth (excluding missing data for 8% of Caucasians and
33% of non-Caucasians), 96% of Caucasian OTR were
born in Europe and 83% of non-Caucasians were born
outside Europe (41% Indian subcontinent, 32% Africa,
11% Caribbean, 10% Far East and 6% Middle East).
Overall HPV seroprevalence by ethnicity and immune 
status
Figure 1 shows the overall seroprevalence for any HPV
type and for each genus by ethnicity across immune sta-
tus. Seroprevalence to at least 1 HPV type were 90%, 91%
and 94% among Caucasians and 87%, 92% and 92%
among non-Caucasian patients for OTR, dialysis and
immunocompetent patients, respectively (both P-values
for heterogeneity across immune status = 0.3). There was
also no statistically significant difference by immune sta-
tus among Caucasian patients whereas non-Caucasian
transplant patients tended to have lower seroprevalence
for any alpha cutaneous and mucosal, and gamma types
than non-Caucasian dialysis patients. Seropositivity to
cutaneous alpha types was also higher in non-Caucasian
immunocompetent individuals (46%) compared to non-
Caucasian OTR (27%).
HPV seroprevalence and ethnicity
Figure 2 shows the odds ratios for being seropositive to
each single HPV type in non-Caucasian versus Caucasian
Adjusted seroprevalence of HPV antibodies among Caucasian patients [243 organ transplant patients, 222 dialysis patients and  102 immunocompetent] and among non-Caucasian patients [166 organ transplant patients, 145 dialysis patients and 50 immu- nocompetent patients] Figure 1
Adjusted seroprevalence of HPV antibodies among Caucasian patients [243 organ transplant patients, 222 
dialysis patients and 102 immunocompetent] and among non-Caucasian patients [166 organ transplant 
patients, 145 dialysis patients and 50 immunocompetent patients].Infectious Agents and Cancer 2009, 4:14 http://www.infectagentscancer.com/content/4/1/14
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patients by immune status. Among transplant recipients,
the prevalence of antibodies against betaHPV5 (Odd
ratios [OR]: 1.7 and 95% confidence interval (CI): 1.0 to
3.1; P = 0.05), and betaHPV93 (OR: 2.3; 95% CI: 1.0 to
5.0; P = 0.05) were higher among non-Caucasian than
Caucasian patients whereas for HPV 1 (OR: 0.4; 95% CI:
(0.2 to 0.6), P < 0.001) and to a lesser extent gammaHPV4
(OR: 0.5; 95% CI: 0.3 to 0.9; P = 0.02) seroprevalence
were lower in non-Caucasian patients. Differences identi-
fied among OTR in relation to ethnicity were corroborated
for HPV93 (dialysis patients - OR: 3.4; 95% CI: 1.4 to 8.5;
P = 0.006; IC - OR not available [0% in Caucasians versus
10% in non-Caucasians]; P-exact = 0.003) and HPV1
(dialysis patients - OR: 0.5; 95%CI: 0.3 to 0.8; P = 0.007;
IC patients - OR: 0.5; 95% CI: 0.2 to 1.0; P = 0.04) and to
lesser extent for HPV4 (dialysis patients - OR: 0.8; 95%CI:
0.5 to 1.3; P = 0.4; IC patients - OR: 0.5; 95% CI: 0.2 to
1.0; P = 0.05), but not for HPV5 or other HPV types
among dialysis and IC patients. Exclusion of non-renal
transplant patients (n = 5) did not materially change
results (data not shown). There was no difference at the
1% level of significance between Caucasian and non-Cau-
casian OTR regarding multiple HPV seropositivity for any
types, any alpha, cutaneous alpha, mucosal alpha, beta,
gamma or other types (nu, mu and 2 not defined types)
(data not shown).
Table 2 shows the seroprevalence for each HPV type
within non-Caucasian OTR patients for the 2 main ethnic
groups (Black [Africa/Afro-Caribbean] versus Asian).
Black patients were more likely to be seroreactive to
mucosal HPV16 (P = 0.01) and HPV13 (P = 0.02), and to
cutaneous HPV7 (P = 0.007) and HPV2 (P = 0.03). Higher
seropositivity for betaHPV 17, 23 and 38 (species 2) and
to betaHPV 5 (species 1) was also observed in Black indi-
viduals compared to Asians. Results on multiple seropos-
itivity between the 90 Asian and the 51 Black OTR
reflected those findings of single seropositivity with Black
patients more likely to be seroreactive to multiple alpha
cutaneous HPV types (count ratio [CR]: 1.6; 95%CI: 1.0 to
Adjusted odds ratios of being seropositive to one human papillomavirus type by immune status and ethnicity Figure 2
Adjusted odds ratios of being seropositive to one human papillomavirus type by immune status and ethnicity.Infectious Agents and Cancer 2009, 4:14 http://www.infectagentscancer.com/content/4/1/14
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Table 2: Seroprevalence for single HPV types among organ transplant patients for the 2 main ethnic groups of non-Caucasian patients
TWO MAIN ETHNIC GROUPS AMONG NON-CAUCASIAN 
PATIENTS
Asian
N = 90
Black
N = 51
age (mean [SD]) 46  [13] 47 [12]
ratio sex (M/F) 1.4 (53/37) 1.2 (28/23)
Mean time since transplantation [SD] 7.9 (6.6) 4.7 (5.1)
genus species types POS (%) POS (%) OR (95%CI) P-het.1
alpha 2 3 7 (8) 4 (8) 0.9 (0.2-3.3) 0.8
4 2 6 (7) 10 (20) 3.6 (1.2-11.3) 0.03
4 27 10 (11) 9 (18) 1.8 (0.6-4.9) 0.3
8 7 2 (2) 9 (18) 9.5 (1.8-49.3) 0.007
9 16 9 (10) 13 (25) 3.7 (1.4-10.0) 0.01
10 6 23 (26) 11 (22) 0.9 (0.4-2.1) 0.8
10 13 5 (6) 9 (18) 4.5 (1.3-15.6) 0.02
beta 1 5 11 (12) 12 (24) 2.9 (1.1-7.5) 0.03
1 8 20 (22) 11 (22) 1.0 (0.4-2.4) 1.0
1 20 8 (9) 7 (14) 1.5 (0.5-4.6) 0.5
1 24 5 (6) 4 (8) 1.5 (0.4-6.1) 0.6
1 36 4 (4) 4 (8) 1.9 (0.4-8.3) 0.4
1 93 5 (6) 8 (16) 3.0 (0.9-10.2) 0.1
2 9 10 (11) 11 (22) 2.4 (0.9-6.5) 0.1
2 15 16 (18) 12 (24) 1.5 (0.6-3.6) 0.4
2 17 12 (13) 18 (35) 4.4 (1.8-11.0) 0.001
2 23 7 (8) 11 (22) 3.7 (1.2-11.2) 0.02
2 38 13 (14) 17 (33) 3.3 (1.4-8.0) 0.007
3 49 13 (14) 7 (14) 0.9 (0.3-2.4) 0.8
3 75 8 (9) 8 (16) 2.0 (0.7-6.0) 0.2
3 76 8 (9) 10 (20) 2.4 (0.9-6.8) 0.1
4 92 8 (9) 8 (16) 1.9 (0.6-5.7) 0.2
5 96 11 (12) 7 (14) 1.2 (0.4-3.4) 0.8
gamma 1 4 14 (16) 7 (14) 0.7 (0.3-2.1) 0.6
1 65 23 (26) 11 (22) 0.6 (0.3-1.5) 0.3
2 95 16 (18) 9 (18) 1.0 (0.4-2.6) 0.9
2 48 14 (16) 9 (18) 1.1 (0.4-2.8) 0.9
3 50 10 (11) 4 (8) 0.9 (0.2-3.4) 0.9
4 60 8 (9) 4 (8) 1.0 (0.2-4.0) 1.0
nu 41 6 (7) 9 (18) 1.1 (0.4-2.8) 0.9
mu 1 1 14 (16) 6 (12) 0.7 (0.3-2.1) 0.6
2 63 15 (17) 12 (24) 1.5 (0.6-3.7) 0.4
ND 101 13 (14) 9 (18) 1.2 (0.5-3.2) 0.7
103 2 (2) 4 (8) 3.1 (0.5-18.5) 0.2
POS: number seropositive patients; N: number; ND: Not defined; Het.: heterogeneity; SD: standard deviation;
M: Male; F: Female. 1 P-values were calculated using logistic regression adjusted for age at recruitment, time
since transplantation and sex.Infectious Agents and Cancer 2009, 4:14 http://www.infectagentscancer.com/content/4/1/14
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2.7; P = 0.05), to multiple mucosal HPV types (CR: 2.0;
95%CI: 1.1 to 3.7; P = 0.02) and to betaHPV of species 2
(CR: 2.4; 95% CI: 1.3 to 4.5; P = 0.006) (data not shown).
HPV seroprevalence by immune status
In Table 3, seroprevalence of the 34 HPV types were exam-
ined, with comparison between OTR, IC and dialysis
patients by ethnic group. No association was found
between HPV seroprevalence and sex or age within each
immune status group (data not shown). As expected
higher antibody response was observed among women
and younger patients for mucosal types, but these results
did not reach statistical significance at the 1% level (data
not shown). Those individuals seropositive to multiple
types of one genus were more likely to be seroreactive to
multiple types of another genus independently of ethnic-
Table 3: Seroprevalence for single HPV types by immune status (transplant, dialysis and immunocompetent individuals)
Ethnicity Caucasians Non-Caucasians
number 102 222 243 50 145 166
immune status IC dialysis OTR IC Dialysis OTR
genus species types % POS % POS % POS P-het1 % POS % POS % POS P-het1
alpha 23 1 11 09 0.7 22 16 7 0.008
4 2 10 11 17 0.07 12 13 11 0.9
42 7 1 01 42 1 0.02 16 20 14 0.4
877 6 9 0.5 16 14 9 0.3
91 6 2 61 81 6 0.1 16 19 14 0.4
10 6 41 36 33 0.4 40 39 26 0.02
10 13 8 11 13 0.2 14 19 11 0.1
beta 1 5 13 15 11 0.6 24 19 16 0.6
1 8 11 15 24 0.008 26 18 23 0.3
12 0 1 52 01 6 0.3 14 22 11 0.03
12 4 1 41 71 1 0.1 12 14 7 0.1
13 68 1 71 5 0.09 14 10 6 0.2
19 30 4 5 - 10 11 10 1.0
2 9 16 22 19 0.4 16 26 15 0.05
21 5 2 02 22 6 0.5 26 23 20 0.7
21 7 2 12 22 5 0.7 28 27 23 0.7
22 34 1 01 2 0.03 20 15 13 0.3
23 8 2 11 92 3 0.7 34 20 22 0.1
34 9 2 22 01 9 0.7 14 22 14 0.1
37 5 1 21 41 4 0.9 14 16 12 0.6
37 6 1 91 51 2 0.4 26 17 13 0.1
49 2 1 51 81 5 0.7 20 21 13 0.1
59 6 2 31 91 5 0.3 18 14 13 0.8
gamma 1 4 46 36 27 0.001 32 31 16 0.004
16 5 2 02 03 0 0.03 16 17 25 0.1
19 5 2 42 32 2 0.9 22 28 18 0.1
24 8 2 62 31 6 0.05 28 31 17 0.01
35 0 1 51 3 80.1 14 17 8 0.05
46 04 4 50.9 41 08 0.4
nu 41 10 7 13 0.2 20 10 16 0.1
mu 1 1 43 37 33 0.2 26 23 15 0.09
26 3 2 82 02 8 0.3 20 23 19 0.7
ND 101 7 8 10 0.6 16 14 15 0.9
103 3 5 7 0.3 845 0.7
IC: Immunocompetent; OTR: Organ transplant patients; ND: Not defined; % POS: percentage of seropositive patients.
1 Heterogeneity tests using logistic regression between immunocompetent, dialysis and transplant Caucasian patients
from London, adjusted for age and sex.Infectious Agents and Cancer 2009, 4:14 http://www.infectagentscancer.com/content/4/1/14
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ity or immune status (data not shown). The overall mean
number of HPV types identified in people was similar
between the three immune groups (6 types [SD: 6], 6 [SD:
7] and 6 [SD: 7] among Caucasian IC, OTR and dialysis
patients and 7 types [SD: 8], 5 [SD: 7] and 6 [7] among
non-Caucasian IC, OTR and dialysis patients).
The only consistent finding across ethnicity groups was
lower HPV4 seroprevalence and, to a lesser extent, gam-
maHPV 48 among OTR compared to IC or dialysis
patients. Among Caucasian patients, seroprevalence of
antibodies against betaHPV8 was 24% in OTR compared
to 15% among dialysis and 11% among immunocompe-
tent individuals (P-value for heterogeneity = 0.008). Oth-
erwise, HPV seroprevalence differed little for most types
across the different immune status groups, after adjust-
ment for age and sex. For multiple HPV seropositivity,
there was also no statistical difference at the 1% level of
significance between the three immune status groups
among Caucasian patients whereas seropositivity to mul-
tiple mucosal alpha HPV types tended to be higher among
dialysis and immunocompetent patients compared to
OTR (data not shown).
Discussion
Little is known of the seroepidemiology of HPV, with the
exception of those mucosal types associated with cancer
of the uterine cervix [3] or with genital warts [2]. We
report here on the seroprevalence and risk factors for 34
HPV types detected using Luminex technology among
243 Caucasian and 166 non-Caucasian OTR without skin
cancer, 367 individuals with end stage renal failure on
dialysis (222 Caucasians and 145 non-Caucasians) and
152 IC individuals (102 Caucasians and 50 non-Cauca-
sians), in order to compare the HPV seroprevalence in
patients with differing immune status and ethnicity. The
aim was to understand better the humoral response of
cutaneous HPV types.
As expected [16], mucosal and cutaneous HPV were ubiq-
uitous with more than 87% of OTR, IC and dialysis
patients, of Caucasian and non-Caucasian origin, being
seroreactive to one or more types. Susceptibility to multi-
ple HPV infections did not seem to be directly related to
immunosuppressive treatments, since IC and dialysis
patients that were found to be seropositive to multiple
HPV types of one genus were also more likely to be sero-
reactive to multiple types of another. It has to be borne in
mind that the groups examined differed in age and sex dis-
tributions, however we did not observe any association
with age and sex in relation to cutaneous HPV types
within ethnic groups and immune status groups.
To our knowledge, no previously reported studies have
investigated the association between the prevalence of
cutaneous HPV antibodies by ethnicity. Consistently
across immune status, we observed statistically significant
differences between Caucasians and non-Caucasians:
betaHPV 93 was higher in non-Caucasians, whereas
muHPV type 1 and to a lesser extent HPV4 seroprevalence
were lower. As most Caucasians were born in Europe and
non-Caucasian outside Europe we were not able to distin-
guish if the observed differences were confounded by
birth country. There were some limitations to our analyses
on ethnicity as diverse groups (Asian, Black [African and
Afro-Caribbean], Far Eastern or other) with different birth
country were all pooled in the non-Caucasian category.
Geographical studies are essential to examine further the
HPV seroprevalence among different ethnicities. Studies
on sexually transmitted diseases such as gonorrhoea and
chlamydia based in London [17,18], Birmingham [19] or
Leeds [2] have reported higher rates in Black compared to
Asian populations. The higher seropositivity observed for
mucosal alphaHPV 16 among Black patients compared to
Asian individuals could support these previous reports.
However, we did not find any significant difference in
HPV6 - with associated genital warts - seroprevalence
between Asian and Black. Interestingly, the only other
clear association was the higher seroprevalence for beta
species 2 observed among Black individuals compared to
Asians which might suggest a similar mode of transmis-
sion. In another study, we found that, among Caucasian
transplant patients without skin cancer, women with a
self-reported history of abnormal smear tests were also
more likely to have higher seroprevalence for alpha
mucosal and beta types, compared to those without such
history (Casabonne et al., this issue), again suggesting a
possible sexual route of transmission for some beta types.
In relation to immune status, we observed that seropreva-
lence of most HPV types did not differ substantially, after
controlling for age and sex, between Caucasian IC individ-
uals, dialysis patients without a history of transplantation
and OTR, suggesting apparently low disturbance in pro-
duction of antibodies by immunological status. The only
notable exception was a lower HPV4 seroprevalence
among OTR compared to dialysis or IC patients inde-
pendent of ethnicity. Unfortunately, we do not have com-
plete information on the type of dialysis (continuous
ambulatory peritoneal dialysis or haemodialysis) to
explore whether this specifically affected seroprevalence.
The observed differences in overall seroprevalence by gen-
era among non-Caucasian patients might be due to the
pooling of very heterogeneous groups of non-Caucasians
[18].
Conclusion
In summary, we did not find major differences in the
prevalence of antibodies against 34 HPV types among
people with different immune states. Ethnicity did showPublish with BioMed Central    and   every 
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significance differences, but results should be interpreted
with caution since ethnic groups with different birth
country, cultural and socioeconomic backgrounds were
pooled together. Further research is needed to clarify the
risk factors and the natural history of these viruses.
List of Abbreviations
HPV: human papilloma virus; OTR: organ transplant
recipients; IC: Immunocompetent; OR: odds ratio; CI:
confidence interval.
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